Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials

Background To the authors' knowledge, in the absence of head‐to‐head trials, it is unclear whether chemoimmunotherapy provides an additional overall survival (OS) benefit compared with immunotherapy alone in the first‐line treatment of patients with advanced non–small cell lung cancer (NSCLC)....

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2021-03, Vol.127 (5), p.709-719
Main Authors: Pathak, Ranjan, De Lima Lopes, Gilberto, Yu, Han, Aryal, Madan Raj, Ji, Wenyan, Frumento, Katherine Stemmer, Wallis, Christopher J. D., Klaassen, Zachary, Park, Henry S., Goldberg, Sarah B.
Format: Article
Language:English
Subjects:
Apoptosis
Bayesian analysis
Cell death
Clinical trials
combination
drug therapy
Immunotherapy
Literature reviews
Lung cancer
Meta-analysis
network
Non-small cell lung carcinoma
Oncology
PD-L1 protein
programmed cell death protein 1 receptor/antagonists and inhibitors
Small cell lung carcinoma
Statistical analysis
Survival
survival analysis
systematic review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background To the authors' knowledge, in the absence of head‐to‐head trials, it is unclear whether chemoimmunotherapy provides an additional overall survival (OS) benefit compared with immunotherapy alone in the first‐line treatment of patients with advanced non–small cell lung cancer (NSCLC). The authors conducted a systematic literature review and network meta‐analysis (NMA) to compare the efficacy of chemoimmunotherapy versus ICI. Methods MEDLINE, Excerpta Medica dataBASE (EMBASE), Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched from inception to April 2020. Phase 3 trials evaluating the efficacy of first‐line ICI or chemoimmunotherapy and reporting efficacy outcomes (OS, progression‐free survival [PFS], and the overall response rate [ORR]) stratified by programmed death–ligand 1 (PD‐L1) status were included. NMA with a Bayesian random effects model was performed. Results A total of 12 eligible trials comprising 7845 patients were included. In patients who were negative for PD‐L1 (tumor proportion score [TPS]
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.33269